Jan Wald
Jan Wald
easily
I think they easily could go up to $76 without a lot of damage.
relationship speech
If the relationship has been adversarial, the FDA, we believe, would not be as accommodating, even in speech.
hurting
I think of all the pieces, it's pharmaceuticals that are hurting them the most.
boston heard scientific single
I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.
ask boston hold holding johnson paper rather whether
If you're a Guidant shareholder, you have to ask yourself whether you'd rather hold Boston paper or Johnson & Johnson paper. I would rather hold Boston, because I'm holding Guidant for growth.
closing concerned delay interest though
Integration is going full-speed ahead. I don't think they would be concerned by a two-week delay in closing the deal, even though there's an interest payment.
certainly company
I certainly think it could be a stand-alone company. I'm not certain it should be.
employees minnesota risk
I don't think there's much risk to employees ? especially the Minnesota contingent.
johnson stronger threat
The combination of Guidant and Johnson & Johnson is a stronger threat to Medtronic,
beginning fourth looked looking quarter
The end of the fourth quarter looked better than the beginning, and 2006 is looking OK.
actions louder speak
This is one of those times when actions speak louder than words.
boston less time worse
The less time they give Boston Scientific, the worse it is for Boston Scientific. They have less time to react.
accused answer both devices medical
In investors' minds, they've been accused of being a one-trick pony, and they don't have a pipeline. If they get Guidant, they answer both those questions. They'll be in one of the fastest-growing medical devices markets, for implantable defibrillators, and they'll have Guidant's pipeline.